Adam Walsh
Stock Analyst at Roth Capital
(2.57)
# 2,351
Out of 5,182 analysts
18
Total ratings
56.25%
Success rate
16.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Reiterates: Buy | $12 | $2.14 | +460.75% | 2 | Apr 17, 2026 | |
| INSM Insmed | Reiterates: Buy | $212 | $105.00 | +101.90% | 2 | Apr 17, 2026 | |
| APLS Apellis Pharmaceuticals | Initiates: Buy | $31 | $41.01 | -24.41% | 1 | Mar 13, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $58 | $31.04 | +86.86% | 1 | Jan 23, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $171 | $246.14 | -30.53% | 3 | Apr 20, 2020 | |
| GLPG Galapagos NV | Maintains: Buy | $121 → $188 | $27.73 | +577.97% | 4 | Jul 15, 2019 | |
| CORT Corcept Therapeutics | Downgrades: Hold | n/a | $51.05 | - | 4 | May 31, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $74 → $77 | $26.13 | +194.68% | 1 | Apr 18, 2018 |
Equillium
Apr 17, 2026
Reiterates: Buy
Price Target: $12
Current: $2.14
Upside: +460.75%
Insmed
Apr 17, 2026
Reiterates: Buy
Price Target: $212
Current: $105.00
Upside: +101.90%
Apellis Pharmaceuticals
Mar 13, 2026
Initiates: Buy
Price Target: $31
Current: $41.01
Upside: -24.41%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $31.04
Upside: +86.86%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146 → $171
Current: $246.14
Upside: -30.53%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121 → $188
Current: $27.73
Upside: +577.97%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $51.05
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74 → $77
Current: $26.13
Upside: +194.68%